Application of calcium peptide in resisting porcine coronavirus
By targeting the integrin β1 protein in the host, it significantly inhibits the infection of pig coronavirus PEDV, TGEV and PDCoV, solving the problem of preventing and controlling pig coronavirus in the prior art, and achieving efficient antiviral effects.
Patent Information
- Application Number
- CN202411233119.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-29
AI Technical Summary
The existing technology is difficult to effectively prevent and control the infection of pig coronavirus PEDV, TGEV and PDCoV, which has caused huge economic losses in the pig farming industry.
Calcitein exerts antiviral function in the early stages of the virus by targeting the integrin β1 protein in the host, significantly inhibits pig coronavirus infection, and has high safety and dose-dependent in Vero, ST and PK-1 cells.
Calcium peptides effectively inhibit the infection of pig coronavirus, especially in the early stages of the virus, have significant antiviral activity, and have demonstrated its safety and application prospects in vitro and mouse experiments.
Smart Images

Figure CN119033745A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, and in particular to the application of calpeptide in resisting porcine coronavirus. Background Art
[0002] Coronavirus is a kind of virus widely existing in nature, belonging to the Coronaviridae family and the Coronavirus genus. Coronavirus is a single-stranded positive-sense RNA virus with an envelope structure and a genome of about 80-120nm. It is the RNA virus with the largest genome size known so far. Coronavirus has a wide host range and can infect a variety of animals including humans, mice, pigs, cats, dogs, etc., and can cause a variety of diseases. In the pig farming industry, special attention should be paid to porcine enteric coronaviruses, such as porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV) and porcine delta coronavirus (PDCoV), which pose a serious threat to the development of the pig farming industry and cause huge economic losses.
[0003] PEDV can cause highly contagious enteric diseases characterized by vomiting, diarrhea and dehydration in pigs of different ages. Since it was first reported in the UK in 1971, the epidemic caused by the virus has successively shown large-scale outbreaks in many countries. In particular, in the past two decades, PEDV has caused three large-scale outbreaks in Asia (2010), North America (2013) and Europe (2014), resulting in a morbidity rate of up to 100% and a mortality rate of 80% to 100% in lactating piglets, causing huge economic losses to the global pig industry. Similarly, TGEV, a pathogen first discovered in the United States in 1946, is currently an important pathogen of pig diseases, which can cause vomiting, watery diarrhea, dehydration and weight loss in pigs. If there is no adequate protection from lactogenic antibodies, the mortality rate of piglets infected with TGEV can reach 70%-100%. At present, TGEV has caused the death of millions of piglets, causing huge economic losses worldwide. Compared with PEDV and TGEV, PDCoV is a new porcine enteric coronavirus that can cause diarrhea, vomiting and dehydration in suckling piglets. In particular, the continuous mutation of the above three viruses and their mixed infection have caused more serious economic losses to the global pig farming industry.
[0004] Calpeptin, a reversible semisynthetic peptidomimetic aldehyde inhibitor of calpain I, calpain II, cathepsin L, and K, has been previously shown to block prion protein shedding and has been shown to be an effective SARS-CoV-2 inhibitor in vitro. However, the role of calpeptin in porcine coronavirus infection has not been reported. Summary of the invention
[0005] The purpose of the present invention is to provide an application of calpeptin in anti-swine coronavirus to solve the problems existing in the above-mentioned prior art. The present invention discloses that calpeptin has significant antiviral activity and effect on porcine coronavirus PEDV, TGEV and PDCoV, and exerts antiviral function in the early stage of the virus by directly targeting integrin β1 protein in the host.
[0006] To achieve the above object, the present invention provides the following solutions:
[0007] Technical Solution 1: Application of calpeptidase in the preparation of products for inhibiting porcine coronavirus infection.
[0008] Furthermore, the porcine coronavirus is porcine epidemic diarrhea virus, porcine transmissible gastroenteritis virus and porcine delta coronavirus.
[0009] Furthermore, the product is a medicine.
[0010] Furthermore, the infection is an early infection.
[0011] The present invention discloses the following technical effects:
[0012] The purpose of the present invention is to effectively solve the defects and deficiencies of the existing porcine coronavirus prevention and control technology, and highlight the application of calpeptin in anti-porcine coronavirus. The present invention reveals that calpeptin has significant antiviral activity and effect on porcine coronaviruses PEDV, TGEV and PDCoV, and exerts antiviral function in the early stage of the virus by directly targeting the integrin β1 protein in the host. Specifically, calpeptin has high safety in Vero, ST and PK-1 cells; calpeptin can inhibit the infection of porcine coronaviruses (PEDV, TGEV and PDCoV) in vitro in a dose-dependent manner; calpeptin can also inhibit the early infection of the virus. In addition, the synthesis process of calpeptin is mature, it is widely used in the field of biomedicine, and the drug has been proven to be safe by mouse experiments, so it has good application prospects in the preparation and development of antiviral drugs for porcine viral coronaviruses. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0014] Figure 1 This is a diagram for the safety validation of calpeptidin in Vero, ST and PK1 cells;
[0015] Figure 2 This is a graph showing the inhibitory effect of calpeptidin on PEDV, TGEV and PDCoV;
[0016] Figure 3 Effects of different doses of calpeptidase on PEDV mRNA and TCID 50 The inhibitory effect diagram;
[0017] Figure 4 The effects of calpeptidase on PEDV mRNA and TCID at different stages 50 Effect diagram of the effect;
[0018] Figure 5 The effect of calpeptidin on PEDV mRNA and TCID 50 Killing effect diagram;
[0019] Figure 6 The figure shows the direct binding of calpeptin to integrin β1 in cells, where A is a Western blot of the CETSA binding of calpeptin to integrin β1 at different temperatures; B is a quantification of the integrin β1 band intensity in the CETSA experiment. DETAILED DESCRIPTION
[0020] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0021] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0022] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0023] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0024] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0025] Example 1
[0026] 1. Solution preparation: Dissolve calpeptin powder (purchased from APExBIO) in DMSO solution, sterilize with a 0.22 μm sterile filter, and prepare calpeptin cell culture solution. After aliquoting, store at -80°C for later use.
[0027] 2. Inoculate Vero, ST and PK1 cells (all from the Animal Disease Prevention and Control Laboratory of Shanxi Agricultural University) in a 96-well plate. After they grow larger than a monolayer, discard the cell culture medium and wash with PBS solution three times. Add 100 μL of the original culture medium of calpeptide with different concentrations (5 μM, 10 μM, 30 μM, 50 μM and 100 μM) respectively. Set up 5 replicates for the treatment groups with different concentrations, and set up a DMSO negative control group and a normal cell control group. After 12 hours of drug treatment, add 10 μL MTT to each well. After 4 hours of MTT incubation, replace the culture medium with 150 μL DMSO. Measure the UV absorbance at 490 nm.
[0028] Depend on Figure 1 It can be seen that the safe concentration of calpeptide in Vero, ST and PK1 cells can reach 100μM.
[0029] 3. Vero, ST and PK1 cells were inoculated into 6-well plates. After they grew into a monolayer, the DMEM medium was discarded and washed three times with PBS solution. Then, the original culture medium containing 10 μM calpeptide and PEDV, TGEV and PDCoV with an MOI of 0.01 were added to the cells for 12 h. At the same time, a DMSO negative control group and three groups of biological replicates were set up. The TCID 50 To analyze the virus infection.
[0030] Depend on Figure 2 It can be seen that compared with the control group, calpeptidin has a significant inhibitory effect on PEDV, TGEV and PDCoV.
[0031] 4. To analyze the inhibitory effect of calpeptin on viral infection, Vero cells were inoculated in 6-well plates. After they grew into a monolayer, the DMEM medium was discarded and washed three times with PBS solution. Then, the original culture medium containing 0μM, 3μM, 4μM, 5μM, 6μM, 7μM, 8μM, 9μM and 10μM calpeptin and PEDV virus solution with an MOI of 0.01 were added to the cells for 12 hours. At the same time, a DMSO negative control group and three groups of biological replicates were set up. TCID 50 To analyze the virus infection.
[0032] Depend on Figure 3 It can be seen that compared with the control group, the inhibitory effect of calpeptidin on PEDV is dose-dependent.
[0033] 5. To analyze the stage of virus infection that calpeptin has an inhibitory effect on, Vero cells were inoculated into 6-well plates. After they grew into a monolayer, the DMEM medium was discarded and the cells were washed three times with PBS solution. After the cells were treated with calpeptin (10 μM) for 1 hour, PEDV virus solution containing MOI of 0.01 was added and cultured for 12 hours, recorded as -1 hour, and placed in a 37°C incubator for 1 hour. The virus solution was then discarded, the cells were washed three times with PBS, and cell maintenance solution was added. Similarly, calpeptin was added at 0h, 1h, 3h, 5h, 7h and 9h of virus infection, respectively, so that the drug concentration reached 10μM. At the same time, a DMSO negative control group was set up. After the above cells were cultured for 12 hours, the mRNA expression level and TCID of the virus were detected by RT-PCR. 50 To analyze the virus infection.
[0034] Depend on Figure 4 It can be seen that compared with the control group, calpeptide administration at four time periods of 0-1h, 1h, 3h and 5h after viral infection had significant inhibitory effects on viral infection, among which the inhibitory effect was particularly significant at 1h after viral infection. The above results indicate that calpeptide inhibits viral infection mainly in the early stages of viral infection.
[0035] 6. To analyze the reasons for the inhibitory effect of calpeptin on the virus, PEDV was incubated with calpeptin (10 μM) and control DMSO in DMEM at 37°C for 1 h. After incubation, Vero cells cultured in monolayers were infected with a 1:100 dilution of the mixture (calpeptin was diluted to an inactive concentration and the infection MOI was 0.01 PEDV virus solution) for 48 hours. TCID 50 Detect virus titer.
[0036] Depend on Figure 5 It can be seen that compared with the control group DMSO, the toxicity of PEDV after mixing with calpeptin did not change significantly, indicating that calpeptin has no killing effect on PEDV.
[0037] 7. To analyze whether calpeptin exerts its antiviral effect by targeting integrin β1, Vero cells cultured in monolayers were washed with PBS and then resuspended in NP40 lysis buffer supplemented with protease inhibitors. The cell lysate was centrifuged at 12000g for 15min at 4°C, and the supernatant was collected. The supernatant was then divided into two equal parts and treated with calpeptin and control DMSO for 1h at room temperature. Each sample was divided into smaller (60μL) aliquots, heated at different temperatures for 5min, and then cooled on ice for 3min. The heated samples were centrifuged at 20000g for 20min at 4°C. Equal amounts of supernatant samples were subjected to SDS-PAGE, then transferred to nitrocellulose (NC) blotting membranes and incubated with anti-integrin β1 for detection. Finally, enzyme-labeled secondary antibodies were added and treated with enhanced chemiluminescence buffer. ImageJ software was used to quantify integrin β1 bands.
[0038] Depend on Figure 6 It can be seen that compared with the control group DMSO, the addition of 10 μM calpeptin significantly increased the Tm of integrin β1, indicating that calpeptin directly binds to integrin β1 in the cell.
[0039] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. Application of calpeptide in the preparation of products for inhibiting porcine coronavirus infection.
2. The use according to claim 1, characterized in that: The porcine coronaviruses are porcine epidemic diarrhea virus, porcine transmissible gastroenteritis virus and porcine delta coronavirus.
3. The use according to claim 1, characterized in that: The product described is a drug.
4. The use according to claim 1, characterized in that: The infection is an early stage infection.
